ArticlePloS one2026

Expedited pathway portfolios, trial complexity, and FDA approval timelines in oncology and neurology: A comparative analysis.

Ahmed M Sayed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.